⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Critère principal de survie globale atteint dans l’essai pivot ROSELLA de phase 3 de Corcept évaluant le rélacorilant chez les patientes atteintes d’un cancer de l’ovaire résistant au platine
businesswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
prnewswire.com
CORT
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
CORT
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
prnewswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
accessnewswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
globenewswire.com
CORT
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect
accessnewswire.com
CORT
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Reach Out
accessnewswire.com
CORT
Levi & Korsinsky Investigates Possible Securities Fraud by Corcept Therapeutics Incorporated (CORT) Ready to Announce with Confidence?
newsfilecorp.com
CORT
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
CORT